Drug-resistant Mycobacterium tuberculosis (Mtb) continues to outrun existing therapies. Cyclic peptides that target the bacterial ClpC1 protein hold promise, but assessing how they modulate the target and selecting strong candidates remains a real challenge. Demissie and colleagues recently compared multiple cyclic peptides head-to-head on Mtb ClpC1 ATPase activity, revealing complex ties between binding, enzymatic effects, and cellular efficacy. The article reviews their key findings and discusses how specialized discovery and purification services can help advance these candidates toward high-quality development.
Tuberculosis causes roughly 1.5 million deaths each year. The spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains has pushed traditional therapies to their limits. So identifying new targets that work through fresh mechanisms has become a pressing priority in antituberculosis drug discovery.
Current treatments primarily target pathways such as cell wall synthesis and nucleic acid transcription, but prolonged use has driven widespread cross-resistance. ClpC1 is an AAA+ ATPase in Mtb that forms a proteolytic complex with ClpP1/P2 and is essential for bacterial protein homeostasis. With no direct human homologue and given that its natural cyclic peptide modulators (such as Cyclomarin A and Rufomycin) have shown potent anti-Mtb activity, ClpC1 is considered a highly promising next-generation drug target.
The cyclic peptides Rufomycin (RUF), Cyclomarin A (CYMA), and Ecumicin (ECU), derived from Streptomyces and Nonomuraea species, all bind to the N-terminal domain of ClpC1 and interfere with the normal function of the ClpC1-ClpP complex. However, whether these cyclic peptides inhibit, activate, or indirectly modulate ClpC1 ATPase activity had not been systematically or quantitatively compared. The study by Demissie and colleagues was designed to fill this gap.
This study established a multidimensional evaluation workflow integrating biochemistry, biophysics, and microbiology, revealing differential modulation patterns of ClpC1 ATPase activity by various cyclic peptides.
The research team compared the Malachite Green assay, the PK/LDH coupled assay, and the ADP-Glo™ luminescence assay, ultimately selecting ADP-Glo™ for subsequent experiments.
Three potential non-radioactive enzyme assays to measure ATPase activity1,5
This method indirectly reflects ATP hydrolysis rates by measuring ADP production and offers advantages including high signal-to-noise ratio, low background, and compatibility with low enzyme concentrations. Optimized conditions were: 80 µM ATP, pH 7.5, 0.125–0.25 µM ClpC1, with a reaction time of 40–60 minutes. This system laid the foundation for quantitative assessment of cyclic peptide modulation.
ATPase assay optimization2,5
The study found that an N-terminal His6-SUMO tag reduced ClpC1 ATPase activity by 4–5 fold, whereas a C-terminal His6 tag had no effect. Truncated constructs (NTD, D1, D1D2, etc.) all showed significantly lower activity than the full-length protein, indicating that the NTD is essential for substrate recognition and enzymatic activity.
Purification and oligomer characterization of His6-SUMO-FL-ClpC1 and native FL-ClpC13,5
Circular dichroism (CD) spectroscopy showed that deletion of the NTD did not alter the secondary structure of D1D2, suggesting that the loss of activity arises from disrupted interdomain coordination. Consequently, all subsequent experiments used full-length tag-free ClpC1.
At 0.125 µM ClpC1, ECU increased ATPase activity by approximately 700% (8-fold activation), RUF by approximately 90%, and CYMA by only approximately 55%. When the ClpC1 concentration was increased to 0.25 µM, ECU activation further rose to 1530%. Although RUF and CYMA had better MIC values (0.02–0.094 µM) than ECU (0.16 µM), their ATPase activation was much weaker. This suggests that strong antibacterial activity does not necessarily correlate with strong ATPase activation, and cyclic peptides may act through multiple mechanisms.
Effects of the three cyclic peptides on FL-ClpC1 ATPase activity4,5
The study further compared ECU and five analogs (norECU, deoxyECU, nordeoxyECU, OMSA, OMSB). The four cyclic peptides with the same tail length (ECU and three analogs) exhibited AC50 values between 0.19 and 0.38 µM, with maximum activation ranging from 470% to 820%. In contrast, the shorter-tailed analogs OMSA and OMSB showed AC50 values of 1.25 µM and 3.05 µM, respectively, with maximum activation reduced to 470% and 236%. SPR binding affinities (KD) followed the same trend: ECU-class KD ranged from 0.042 to 0.18 µM, while OMSB reached 2.15 µM. Molecular docking indicated that the hydrophobic surface formed by residues L92 and L96 interacts with the tail region of these cyclic peptides; tail shortening weakens this interaction, leading to reduced activity.
Although MIC, KD, and AC50 values showed some correlation, each reflects a different dimension: KD measures binding strength, AC50 reflects half-maximal effective concentration for enzyme modulation, maximum activation indicates efficacy, and MIC represents cellular antibacterial outcomes. RUF and CYMA belong to the high-affinity, low-ATPase-activation class, while ECU and its analogs belong to the moderate-affinity, high-ATPase-activation class. This mechanistic distinction suggests that relying on a single parameter in cyclic peptide drug screening may miss important information, making multiparameter orthogonal assessment strategies necessary.
The above study demonstrates a complete pathway for high-quality cyclic peptide characterization. However, when translating similar projects from literature reproduction to actual lead discovery, research teams often encounter several practical obstacles.
Target protein preparation is difficult (ClpC1 is large, aggregation-prone, tag-sensitive; low yield of tag-free full-length protein limits screening). Cyclic peptide libraries lack diversity (over-reliance on known natural products or simple analogs). SAR progression is slow (de novo analog synthesis requires robust cyclization and purification; impurities mislead interpretation). Early developability assessment is often missing (solubility, stability, nonspecific binding rarely evaluated at hit stage, raising late-stage attrition risk).
Cyclization side reactions—like incomplete cyclization, dimerization, or epimerization—create messy impurity profiles. Unlike linear peptide impurities, these cyclic byproducts often have similar polarity to the target, so standard C18 columns can't separate them well. Plus, confirming cyclization sites, checking structural integrity, or telling apart conformational isomers goes way beyond routine mass spec. The ADP-Glo™ and SPR assays used in the paper need high-purity samples; impurities throw off KD and AC50 readings. So cyclic peptide projects really need specialized purification and analytical strategies from early discovery all the way through preclinical candidate selection.
To address the bottlenecks described above, Creative Peptides provides integrated services spanning cyclic peptide library design, hit discovery, SAR optimization, and high-quality purification and characterization. Our goal is not simply to synthesize compounds but to help you generate credible, actionable, and translatable cyclic peptide leads.
| Services | Contents |
| Cyclic Peptide Drug Discovery Services | For targets such as ClpC1 that have defined binding pockets but are conformationally dynamic, we help clients design appropriate cyclic peptide discovery strategies. Our service modules include:
This closed-loop workflow directly addresses the conclusion of the literature study that multiparameter comprehensive assessment is needed, helping you build a complete understanding of cyclic peptide candidates from the hit stage onward. |
| Analytical Characterization of Cyclic Peptides | Whether for hits from library screening or leads from SAR optimization, high purity is a prerequisite for obtaining reliable KD, AC50, and MIC data. Our purification and analytical characterization services are specifically designed for the unique impurity profiles of cyclic peptides:
|
Creative Peptides provides end-to-end support for cyclic peptide discovery—library design, screening, optimization, purification, and characterization. Whether you are starting with a difficult target or already have hits you want to advance, we can help.
Ready to move your project forward? Contact our scientific team to discuss your target, your molecules, and your challenges. Let's turn mechanistic insights into real candidates.
References
